Approved Study Database

Ref. No. Scientific Title Principal investigator
2003.031 Role of High Dose Oral Rabeprazole in Prevention of Peptic Ulcer Rebleeding Dr. Wu Che Yuen Justin
2002.501 Symptomatic Gastroesophageal Reflux Disease: Double Blind Randomized Controlled Study of On-Demand Therapy Versus Maintenance Therapy Dr. Wu Che Yuen Justin
2001.474 Is Visceral Hyperalgesia The Culprit Of Noncardiac Chest Pain in Chinese? Dr. Wu Che Yuen Justin
2004.099 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Evaluation of the Efficacy and Safety of Tegaserod (6mg b.I.d.), Administered Orally for 12 Weeks, in Male Patients with Chronic Constipation Dr. Wu Che Yuen Justin
2006.257 Treatment Response in Patients with Symptoms due to Gastroesophageal Reflux Disease Either with or without Esophagitis Treated with Pantoprazole Sodium 40mg o.d. over 8 Weeks (BY1023/M3-341) Dr. Wu Che Yuen Justin
2005.192 The Efficacy of Imipramine in Treatment of Functional Dyspepsia: A Double Blind Randomized Placebo Controlled Trial Dr. Wu Che Yuen Justin
2004.253 Endoscopic Treatment of Gastroesophageal Reflux Disease with Injectable Biopolymer (Enteryx_): A Pilot Study in Asian Population Dr. Wu Che Yuen Justin
2005.186 A Prospective Randomized Comparison of A Novel Hemostatic Clip (Resolution Clip Dr. Wu Che Yuen Justin
2005.311 Seroprevalence of Subclinical Celiac Disease in Patients with Overlapping Functional Gastrointestinal Disorders WU Che Yuen Justin
2011.491 Use of the PHQ-4 for screening of and treatment preference on depression and axiety in Hong Kong Chinese patients WU Chun Yu
2003.278 Development of a Novel Disease-Specific Quality of Life Questionnaire for Gastroesophageal Reflux Disease (GERD) Patients in Chinese Popluation WU CY Justin
2007.285 Quality of Life in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Their Parents in Hong Kong, China XIANG Yu Tao
2005.094 Subjective Quality of Life of Outpatients with Schizophrenia in Hong Kong and Beijing: The Role of Socio-demographic and Clinical Factors XIANG Yutao
2005.211 Management of Drooling for Children with Neurological Problems in Hong Kong YAM Ka Ling Winnie
2003.335 Reliability and Validity of the Chinese Health-related Quality of Life Measure for Youth with Epilepsy YAM Ka Ling Winnie
2002.505 Reliability of the Modified Ashworth Scale and the Modified Tardieu Scale in the Assessment of Lower Limb in Children with Cerebral Palsy YAM Ka Ling Winnie
2010.343 Difficulties, satisfaction, and coping strategies of the family caregivers of stroke survivors YAM Yim Ling
2007.175 Identification of Adult Stem Cell Markers and their Roles in Maintenance of Plurioptency YAN Hin Fai Gary
2011.534 Type D personality in patients contemplating coronary revascularization YAN Ping Yen Bryan
2011.234 Predicting Outcomes in Acute Coronary Syndrome: A Translational Approach Integrating Population-Specfic Clinical Risk Models, Platelet Reactivity and Metabolomic Biomarkers YAN Ping Yen Bryan
2011.237 Management and Prognosis of Patients with Minor Coronary Artery Disease YAN Ping Yen Bryan
2012.131 Psychiatric Morbidity in Adult Patients with Cervical Dysplasia in a Colposcopy Clinica in Hong Kong YAN Tin Yee Connie
2005.262 Intervention of Drooling in Children with Neurological Disability YANG Li Chien Hellen (No email contact)
2007.507 Studies on a New Therapeutic Strategy to Enhance mRNA / Protein Expression of Endothelial Nitric Oxide Synthase (eNOS) and NO-related Function in Disease - Use of eNOS Enhancer YANG Qin
2004.313 To Test the Reliability of Richmond Agitation Sedation Score (RASS score) in an Adult ICU YAP Hui Yi Florence
2009.082 Prevalence of depressive disorder among Chinese chronic pain patients in Hong Kong YAP Jacqueline
2010.122 Detection of Patent Foramen Ovale in Young Patients with Stroke by Transthoracic Saline Contrast Echocardiography in Hong Kong Yat Yin LAM
2005.417 Effectiveness of Soft Versus Rigid Splinting Designs for First Carpometacarpal Joint Arthritis YAU Carmen
2006.148 Quality of Life of Nasopharyngeal Cancer (NPC) Patients at Diagnosis and 5+ years after Radical Radiotherapy; A Hong Kong Experience Using SF-36v2 and Norm-based Scoring Algorithm YAU Sau Han
2004.421 A Phase III Randomized, Double-Blind Study to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated with Adriamycin-Cyclophosphamide Adjuvant Chemotherapy in Chinese Breast Cancer Patients Prof. Yeo Winnie
2004.091 A Phase III, Randomized Open Label Multicenter Study Comparing GW572016 and Capecitabine (Xeloda) Versus Capecitabine in Women with Refractory Advanced or Metastatic Breast Cancer Prof. Yeo Winnie
2002.062 Randomized Double Blind Trial of Megestrol Acetate Versus Placebo for the Treatment of Inoperable Hepatocellular Carcinoma: An Asia-Pacific Hepatocellular Carcinoma Trials Group Prof. Yeo Winnie
2005.463 Novel Therapeutics Using Inhibitor of histone Deacetylation - PXD101 - by Targeting Epigenetic Biomarkers for Hepatocellular Carcinoma YEO Winnie
2002.469 A Randomized, Double-blind, Parallel-group Study Conducted Under In-house Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting Associated with Moderately Emetogenic Chemotherapy (Revised : CRE-2002.321-T) Prof. Yeo Winnie
2006.263 Detection of Circulating Tumor Cells in Patients with Breast Cancer YEO Winnie
2002.111 Phase II Study of Gemcitabine/Carboplatin Combination Chemotherapy As First Line Therapy Or Recurrent Or Metastatis Breast Cancer Prof. Yeo Winnie
2006.414 A Randomized, Double-Blind, Parallel Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated with Moderately Emetogenic Chemotherapy Prof. Yeo Winnie
2005.197 An Open-Label Multicenter Randomized Phase 3 Study Comparing the Combination of DOXIL_/CAELYX_ and YONDELIS Prof. Yeo Winnie
2006.355 A Randomized 2-Arm, Open-Label, Phase II Study of BMS-582664, Administered Orally at A Dose of 800mg Daily or Doxorubicin Administered Intravenously At A Dose of 60 mg/m2 Every 3 Weeks In Patients with Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Prof. Yeo Winnie
2002.433 Hepatitis B Virus-Related Complications of Cytotoxic Chemotherapy in Patients with Inoperable Hepatocellular Carcinoma Prof. Yeo Winnie
2005.418 A Randomized Double-Blind Phase-2 Study of Anastrozole Plus Lonafarnib (SCH 66336) or Anastrozole Plus Placebo for the Treatment of Subjects With Advanced Breast Cancer Prof. Yeo Winnie
2007.247 An Open-Label Multicenter Study Administering Lapatinib and Capecitabine (Xeloda) in Women with Advanced or Metastatic Breast Cancer Prof. Yeo Winnie
2006.205 An Open Label International Multi-Center Phase 2 Activity and Safety Study of SU011248 in Patients with Advanced / Metastatic Gastric Cancer Progressing or Recurring After One Prior Chemotherapy Prof. Yeo Winnie
2005.369 Randomized Phase II Study of the Combination of Oral Vinorelbine With Capecitabine Versus A Sequential Regimen of Oral Vinorelbine and Capecitabine Versus the Combination of Docetaxel and Capecitabine in Patients with Metastatic Breast Cancer Previously Treated with Anthracyclines Prof. Yeo Winnie
2001.415 A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination with Doxorubicin and Cyclophosphamide (TAC) Versus Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC_T) as Adjuvant Treatment of Operable Breast Cancer Her2neu Negative Patients with Positive Axillary Lymph Nodes Prof. Yeo Winnie
2007.199 An Open-Label, Phase 2 Study of Efficacy and Tolerability of ABT-869 in Advanced Hepatocellular Carcinoma (HCC) Prof. Yeo Winnie
2003.164 Amonafide: Individual Phenotype-Adjusted Chemotherapy for Women with Metastatic Breast Cancer Who have Progressed Despite Prior Chemotherapy Prof. Yeo Winnie
2006.226 A Randomized, Double Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing the Activity of Paclitaxel Plus Trastuzumab Plus Lapatinib to Paclitaxel Plus Trastuzumab Plus Placebo in Women with ErbB2 Overexpressing Metastatic Breast Cancer Prof. Yeo Winnie
2006.230 An Open Label International Multi-Center Phase 2 Activity and Safety Study of SU011248 in Patients with Unresectable Hepatocellular Carcinoma YEO Winnie
2005.020 A Phase II Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled, Dose-Ranging, Parallel Group Study of the Safety and Efficacy of The Oral Neurokinin-1 Receptor Antagonist, GW679769 When Administered as a Daily Doses of 50mg, 100mg and 150mg Oral Tablets in Combination with Ondansetron Hydrochloride and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Subjects Receiving Highly Emetogenic Cisplatin-based Chemotherapy Prof. Yeo Winnie

Page 43 of 254.